Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6894962 | 0.86 | MAOA (0.40) | POLBTRPA1 | |
| SCHEMBL7718360 | 0.83 | GPR119 (0.44) | GPR119KITACHE | |
| SCHEMBL4316504 | 0.80 | GPR119 (0.43) | GPR119POLBKIT | |
| SCHEMBL4317802 | 0.79 | MAOA (0.40) | — | |
| SCHEMBL4003917 | 0.79 | GPR119 (0.48) | GPR119POLBKITPDE10AACHE | |
| SCHEMBL7718355 | 0.79 | SLC6A7 (0.38) | POLB | |
| SCHEMBL15156208 | 0.78 | GAA (0.51) | POLBEPHX2 | |
| SCHEMBL4317148 | 0.75 | KDM4E (0.41) | TRPA1 | |
| SCHEMBL5242132 | 0.75 | PDE10A (0.49) | GPR119POLBKITPDE10AACHE | |
| SCHEMBL1037176 | 0.74 | SLC2A1 (0.54) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337518-B1 | PIPERAZINYLPYRAZINES COMPOUNDS AS ANTAGONISTS OF SEROTONIN 5-HT2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2009-06-17 | — | — | EP | disclosed |
| US-6756377-B2 | PIPERAZINYL)-3-(2-(3-(4-MORPHOLINYLMETHYL)PHENOXY)ETHOXY) PYRAZINE DERIVATIVES; FOR PROPHYLAXIS OR TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM AB (SE) | 2004-06-29 | — | — | US | disclosed |
| EP-1337518-A1 | PIPERAZINYLPYRAZINES COMPOUNDS AS ANTAGONISTS OF SEROTONIN 5-HT2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| US-20020103204-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-08-01 | — | — | US | disclosed |
| WO-2002040457-A1 | PIPERAZINYLPYRAZINES COMPOUNDS AS ANTAGONISTS OF SEROTONIN 5-HT2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103204-A1 | Novel compounds and their use | HTR2C, HTR1A, HTR1B | GPR119 80/4885POLB 4741/4885TRPA1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.